<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122649">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819272</url>
  </required_header>
  <id_info>
    <org_study_id>LCRM105</org_study_id>
    <nct_id>NCT01819272</nct_id>
  </id_info>
  <brief_title>12-Week, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Metformin DR in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elcelyx Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elcelyx Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of delayed-release metformin to placebo on glycemic control (fasting
      plasma glucose and HbA1c) and body weight when administered in subjects with type 2 diabetes
      mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in fasting plasma glucose (mg/dL) at 4 weeks</measure>
    <time_frame>Baseline and 4 weeks after the first dose of study medication</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability at 4 weeks</measure>
    <time_frame>Baseline through 4 weeks after the first dose of study medication</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (mg/dL) at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks after the first dose of study medication</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability at 12 weeks</measure>
    <time_frame>Baseline through 12 weeks after the first dose of study medication</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (%) at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks after the first dose of study medication</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Met DR 600 mg once daily in the morning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delayed-release metformin 600 mg QD in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Met DR 800 mg QD once daily in the morning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delayed-release metformin 800 mg QD in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Met DR 1000 mg once daily in the morning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delayed-release metformin 1000 mg QD in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Met XR 1000 mg once daily in the evening</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extended-release metformin 1000 mg QD in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Met XR 2000 mg once daily in the evening</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Extended-release metformin 2000 mg QD in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily in the morning</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo QD in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>delayed-release metformin</intervention_name>
    <arm_group_label>Met DR 600 mg once daily in the morning</arm_group_label>
    <arm_group_label>Met DR 800 mg QD once daily in the morning</arm_group_label>
    <arm_group_label>Met DR 1000 mg once daily in the morning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extended-release metformin</intervention_name>
    <arm_group_label>Met XR 1000 mg once daily in the evening</arm_group_label>
    <arm_group_label>Met XR 2000 mg once daily in the evening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female with type 2 diabetes who are ≥18 and ≤65 years of age at Visit 1.

          2. Has a BMI of 25.0 kg/m2 to 45.0 kg/m2, inclusive, at Visit 1.

          3. Screening HbA1c 7.0 to 9.5% (inclusive) at Visit 1 if treated with diet and exercise
             alone,  or 6.0 to 9.5% (inclusive) if on a stable dose of either metformin or DPP-4
             inhibitor monotherapy for a minimum of 2 months at Visit 1, or a combination of these
             2 agents only on a stable regimen for a minimum of 2 months at Visit 1.

          4. Has serum creatinine below the upper limit of normal at Visit 1 and an estimated
             glomerular filtration rate (eGFR) of ≥90 mL/min/1.73 m2 based on the Modification of
             Diet in Renal Disease (MDRD) equation: eGFR (mL/min/1.73 m2) = 175 x (Scr, std)-1.154
             x (Age)-0.203 x (0.742 if female) x (1.212 if African American).

          5. Has a fasting glucose concentration of &lt;280 mg/dL at Visit 1.

          6. Has a stable body weight, i.e., not varying by &gt;5% for at least 6 months prior to
             Visit 1 as documented by the investigator.

          7. Is male, or is female and meets all of the following criteria:

               1. Not breastfeeding

               2. Negative pregnancy test result (human chorionic gonadotropin, beta subunit
                  [βhCG]) at Visit 1 (not applicable to hysterectomized females)

               3. If of child bearing potential (including perimenopausal women who have had a
                  menstrual period within 1 year), must practice and be willing to continue to
                  practice appropriate birth control (defined as a method which results in a low
                  failure rate, i.e., less than 1% per year, when used consistently and correctly,
                  such as implants, injectables, hormonal contraceptives,  intrauterine
                  contraceptive devices (IUD), sexual abstinence, tubal ligation or occlusion,
                  condom with spermicide or a vasectomized partner) during the entire duration of
                  the study.

          8. Has a physical examination and ECG with no clinically significant abnormalities as
             judged by the investigator at Visit 1.

          9. Has no clinically significant laboratory test values (clinical chemistry, hematology,
             urinalysis) other than those expected in subjects with diabetes as judged by the
             investigator at Visit 1.

         10. Either is not treated with or has been on a stable treatment regimen with any of the
             following medications for a minimum of 2 months prior to Visit 1:

               1. Hormone replacement therapy (female subjects)

               2. Oral contraceptives (female subjects)

               3. Antihypertensive agents

               4. Lipid-lowering agents

               5. Thyroid replacement therapy

               6. Antidepressant agents

               7. Testosterone therapy (male subjects)

         11. If on chronic thyroid pharmacologic therapy, has a serum thyroid-stimulating hormone
             (TSH) test result within the normal range at Visit 1.

         12. Is willing and able to follow study procedures.

         13. Is able to read, understand, and sign the Informed Consent Form (ICF) and an
             Authorization to Use and Disclose Protected Health Information form (consistent with
             Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation),
             answer the study questions, communicate with the investigator, and understand and
             comply with protocol requirements.

        Exclusion Criteria:

          1. Has a clinically significant medical condition that could potentially affect study
             participation and/or personal well-being, as judged by the investigator, including
             but not limited to the following conditions:

               1. Hepatic disease

               2. Renal disease

               3. Gastrointestinal disease

               4. Endocrine disorder except type 2 diabetes mellitus

               5. Cardiovascular disease

               6. Central nervous system diseases

               7. Psychiatric or neurological disorders

               8. Organ transplantation

               9. Chronic or acute infection (e.g., tuberculosis, human immunodeficiency virus,
                  hepatitis B virus, or hepatitis C virus)

              10. Orthostatic hypotension, fainting spells or blackouts

              11. Allergy or hypersensitivity

          2. Clinically significant malignant disease (with the exception of basal and squamous
             cell carcinoma of the skin) within 5 years of Visit 1.

          3. Has known hypersensitivity, intolerability, or allergies to metformin HCl or any
             component of study treatment.

          4. Has physical, psychological, or historical finding that, in the investigator's
             opinion, would make the subject unsuitable for the study.

          5. Currently abuses drugs or alcohol or has a history of abuse that in the
             investigator's opinion would cause the individual to be noncompliant with study
             procedures.

          6. Had major surgery or a blood transfusion within 2 months of Visit 1 or is planning to
             donate blood during the study, or had a significant blood loss within 2 months prior
             to Visit 1.

          7. Has been treated, is currently being treated, or is expected to require or undergo
             treatment with any of the following  excluded medications:

               1. Insulin or sulphonylurea treatment within 3 months of Visit 1.

               2. GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of
                  Visit 1.

               3. Nifedipine within 3 months of Visit 1.

               4. Systemic corticosteroids by oral, intravenous, intra-articular, or
                  intra-muscular route within 30 days of screening or for more than 1 week within
                  3 months of Visit 1.

               5. Prescription weight loss medications within 3 months of Visit 1.

               6. Chronic or frequent use, in the judgment of the investigator, of any drug
                  treatment that affects gastric pH (prescription or over-the-counter), including
                  proton pump inhibitors or any antacids or medications such as Rolaids or Pepcid
                  within 1 month of Visit 1.

               7. Has received or plans to receive any iodinated contrast dye within 1 week prior
                  to Visit 1 (Screening).

          8. Has had a surgical gastrointestinal procedure that may impact the gut hormonal
             response to study medication.

          9. History or presence of inflammatory bowel disease or other severe gastrointestinal
             disease, particularly those which may impact gastric emptying, such as gastroparesis,
             pyloric stenosis, gastric bypass surgery or gastric banding surgery.

         10. Has received any investigational drug within 30 days (or five half-lives of the
             investigational drug, whichever is greater) of Visit 1.

         11. Is an immediate family member (spouse, parent, child, or sibling; biological or
             legally adopted) of personnel directly affiliated with the study at the clinical
             study site, or is directly affiliated with the study at the clinical study site.

         12. Is employed by Elcelyx Therapeutics, Inc. (that is an employee, temporary contract
             worker, or designee responsible for the conduct of the study).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Searcy</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>May 17, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
